Wu H S
Shanghai Chest Hospital.
Zhonghua Zhong Liu Za Zhi. 1989 Jul;11(4):297-9.
Clinical and basic investigations suggest that perioperative blood transfusions may increase cancer recurrence by nonspecific immunosuppression. Fifty-three patients with Stage I (No) lung cancer treated by surgery in the University of Chicago Medical Center from 1970 to 1986 are reported. There were 18 squamous carcinoma, 29 adenocarcinoma and 6 large cell carcinoma. Of these 53 patients, 30 (57%) received blood transfusion (BT) and 23 (43%) did not (non-BT). A disease-free survival rates of BT and non-BT groups were 43.3% (13/30) and 78.3% (18/23), respectively. Mortality rates after recurrence of BT and non-BT groups were 46.7% (14/30) and 8.7% (2/23) (P less than 0.01). Difference in mortality rates of patients who received red blood cells only (30.8%) and multiple blood transfusions (58.8%), was not significant (P greater than 0.05). This study confirms others reports that perioperative blood transfusions may adversely influence the survival of Stage I (No) lung cancer patients.
临床和基础研究表明，围手术期输血可能通过非特异性免疫抑制增加癌症复发率。本文报告了1970年至1986年在芝加哥大学医学中心接受手术治疗的53例I期（无转移）肺癌患者。其中有18例鳞状细胞癌、29例腺癌和6例大细胞癌。在这53例患者中，30例（57%）接受了输血（BT），23例（43%）未接受输血（非BT）。BT组和非BT组的无病生存率分别为43.3%（13/30）和78.3%（18/23）。BT组和非BT组复发后的死亡率分别为46.7%（14/30）和8.7%（2/23）（P<0.01）。仅接受红细胞输血的患者（30.8%）和多次输血的患者（58.8%）的死亡率差异不显著（P>0.05）。本研究证实了其他报告，即围手术期输血可能对I期（无转移）肺癌患者的生存产生不利影响。
